Badri N. Dasu - Feb 6, 2023 Form 4 Insider Report for ACELRX PHARMACEUTICALS INC (ACRX)

Role
Chief Engineering Officer
Signature
/s/ Martha Adler, Attorney-In-Fact
Stock symbol
ACRX
Transactions as of
Feb 6, 2023
Transactions value $
-$925
Form type
4
Date filed
2/8/2023, 03:51 PM
Previous filing
Mar 4, 2022
Next filing
Feb 14, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRX Common Stock Tax liability -$925 -458 -2.95% $2.02 15.1K Feb 6, 2023 Direct F1, F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs.
F2 Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
F3 Balance includes non-reportable acquisition of 500 shares of Common Stock through the Company's Employee Stock Purchase Plan.
F4 Reflects a 1-for-20 reverse stock split which became effective on October 25, 2022.